

APPENDIX

Supplement #1 search strategies: Prostate cancer guidelines searches	
Database	Results (January 30, 2025)
Ovid Medline	626
Embase.com	187
TRIP Database	98
Guidelines Central	33
Guidelines International Network	40
ECRI	21
Total (with duplicates)	1,005
Duplicates	161
Total (duplicates removed)	844

Ovid Medline

n = 626

1. exp Neoplasms/ and exp Prostate/
2. exp Prostatic Neoplasms/
3. ((prostate or prostatic) adj2 (cancer* or neoplasm*)).ti
4. or/1-3
5. (Guideline or "Practice Guideline" or "Consensus Development Conference" or "Consensus Development Conference, NIH").pt.
6. (guideline or guidelines or (consensus* adj1 (expert or conference OR meeting OR statement)) or recommendations).ti.
7. ("practice parameter*" or "position statement*" or "policy statement*" or CPG or CPGs or "best practice*").ti.
8. (care adj2 (path or paths or pathway or pathways or map or maps or plan or plans or standard*)).ti.
9. ((critical or clinical or practice) adj2 (path or paths or pathway or pathways)).ti.
10. ((critical or clinical or practice) adj2 protocol*).ti NOT ("study protocol*" OR "trial protocol*").ti
11. (algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti.
12. (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti.
13. or/6-12
14. "Journal Article".pt.
15. 13 AND 14
16. 15 not ("Clinical Trial Protocol" or "Case Reports").pt.
17. 5 OR 16
18. 4 AND 17
19. limit 18 to (english language and humans)
20. limit to yr="2015-Current"
21. ..dedup 20

Embase.com

Tondroanamag et al. Few prostate cancer guidelines are of high methodologic quality and therefore trustworthy

N = 187

1. 'cancer'/exp AND 'prostate'/exp
2. 'prostate cancer'/exp
3. ((prostate OR prostatic) NEAR/2 (cancer* OR neoplasm*)):ti
4. #1 OR #2 OR #3
5. 'clinical practice guideline'/exp OR 'medical guideline'/exp OR 'practice guideline'/exp OR 'consensus development'/exp
6. (guideline or guidelines or (consensus* NEAR/1 (expert or conference OR meeting OR statement)) or recommendations):ti
7. ("practice parameter*" or "position statement*" or "policy statement*" or CPG):ti
8. (care NEAR/2 (path or paths or pathway or pathways or map or maps or plan or plans or standard*)):ti
9. ((critical or clinical or practice) NEAR/2 (path or paths or pathway or pathways)):ti
10. ((critical or clinical or practice) NEAR/2 protocol*):ti NOT ("study protocol*" OR "trial protocol*"):ti
11. (algorithm* NEAR/2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)):ti
12. (algorithm* NEAR/2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)):ti
13. #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
14. 'article':it
15. #13 AND #14
16. #5 OR #15
17. #4 AND #16
18. 'conference abstract':it OR 'preprint':it
19. #17 NOT #18
20. #19 NOT [medline]/lim
21. #20 AND [humans]/lim AND [english]/lim
22. #21 AND [2015-2025]/py

TRIP Database

N = 98

title:"prostate cancer*" OR title:"prostatic cancer*" OR title:"prostate neoplasm*" OR title:"prostatic neoplasm*" from_date:2015 to_date:2025

limited to Guidelines

Guideline Central

N = 33

Search: prostate

Guidelines International Network

N = 40

Search: prostate cancer

ECRI

Tondroanamaq et al. Few prostate cancer guidelines are of high methodologic quality and therefore trustworthy

N = 21

"prostate cancer*" OR "prostatic cancer*" OR "prostate neoplasm*" OR "prostatic neoplasm*"

Supplement #2 Excluded Studies:

Guidance Documents Excluded at the Full-Text Review Stage

- [1] Borkowetz A, Blana A, Bohmer D, Cash H, Ehrmann U, Franiel T, et al. German S3 Evidence-Based Guidelines on Focal Therapy in Localized Prostate Cancer: The First Evidence-Based Guidelines on Focal Therapy. *Urol Int.* 2022;106:431-9.
- [2] British Columbia Ministry of Health, BC Guidelines.ca: Prostate Cancer Part 1: Diagnosis and Referral in Primary Care. Aril 15, 2020.
<https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/prostate-cancer-part-1>
- [3] Climent MA, Leon-Mateos L, Gonzalez Del Alba A, Perez-Valderrama B, Mendez-Vidal MJ, Mellado B, et al. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. *Crit Rev Oncol Hematol.* 2015;96:308-18.
- [4] Dunn J, Green A, Ralph N, Newton RU, Kneebone A, Frydenberg M, et al. Prostate cancer survivorship essentials framework: guidelines for practitioners. *BJU Int.* 2021;128 Suppl 3:18-29.
- [5] Ploussard G, Fiard G, Barret E, Brureau L, Crehange G, Dariane C, et al. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. *Prog Urol.* 2022;32:1275-372.
- [6] Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P, Clinical Guidelines Committee of the American College of P. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. *Ann Intern Med.* 2013;158:761-9.